SHANGHAI – Fangzhou Inc. () and Shanghai Tenry Pharmaceutical Co., Ltd. announced today a strategic partnership to develop AI-driven chronic disease management services, according to a press release statement. The $128 million market cap Fangzhou currently trades below its Fair Value, with InvestingPro assigning the company a “GREAT” financial health score of 3.57 out of 5.
The agreement was formalized at the 92nd PHARMCHINA conference in Shanghai. Under the partnership, Tenry Pharmaceutical’s GLP-1 therapy Paidakang® (injectable vipeglutide) will be made available through Fangzhou’s Internet hospital platform nationwide.
Fangzhou operates an online chronic disease management platform serving 56.4 million registered users and 251,000 physicians as of December 31, 2025. The company utilizes its Xingshi Large Language Model to power AI tools including AI Medication Assistant, AI Doctor Assistant and AI Health Manager. According to InvestingPro Tips, Fangzhou holds more cash than debt on its balance sheet and maintains strong profitability with a return on equity of 30%. Subscribers have access to 8 additional exclusive ProTips for deeper investment insights.
Paidakang® was developed by PegBio Co., Ltd. () for treatment of type 2 diabetes and metabolic disorders. Clinical studies showed patients achieved sustained glycemic control over 52 weeks. The therapy requires no dosage titration. Tenry Pharmaceutical obtained exclusive commercialization rights for the drug in mainland China in March 2026.
The collaboration combines Fangzhou’s digital healthcare infrastructure with Tenry Pharmaceutical’s drug portfolio. The companies stated the partnership aims to expand access to chronic disease management services for metabolic diseases across China.
Both parties indicated plans to develop additional applications under an AI-integrated chronic disease service model. The partnership supports the government’s Healthy China 2030 initiative, according to the companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.